Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Summary

This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.

Timeline

Start

2022-10-31

Primary completion

2025-05-22

Completion

2025-07-17

Outcome

Outcome not reported

Stopped (Business): “The study was ended earlier than planned due to a sponsor decision.”

Drugs

Indications